Document Detail


Application of SBDD to the Discovery of New Antibacterial Drugs.
MedLine Citation:
PMID:  22222458     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The emergence of bacteria that are multiply resistant to commonly used antibiotics has created the medical need for novel classes of antibacterial agents. The unique challenges to the discovery of new antibacterial drugs include the following: spectrum, selectivity, low emergence of new resistance, and high potency. With the emergence of genomic information, dozens of antibacterial targets have been pursued over the last 2 decades often using SBDD. This chapter reviews the application of structure-based drug design approaches on a selected group of antibacterial targets (DHFR, DHNA, PDF, and FabI) where significant progress has been made. We compare and contrast the different approaches and evaluate the results in terms of the biological profiles of the leads produced. Several common themes have emerged from this survey, resulting in a set of recommendations.
Authors:
John Finn
Related Documents :
19198298 - The synthesis of high molecular weight partially hydrolysed poly(vinyl alcohol) grades ...
17582748 - Mechanistic evaluation of factors affecting compound loading into ion-exchange fibers.
18359208 - Microspheres for colonic delivery of ketoprofen-hydroxypropyl-beta-cyclodextrin complex.
19669098 - Novel biodegradable polylactide/poly(ethylene glycol) micelles prepared by direct disso...
8106838 - Effects of mipragoside on ocular allergic inflammation in the rabbit.
21206438 - Definition of intractable epilepsy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Methods in molecular biology (Clifton, N.J.)     Volume:  841     ISSN:  1940-6029     ISO Abbreviation:  Methods Mol. Biol.     Publication Date:  2012  
Date Detail:
Created Date:  2012-01-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9214969     Medline TA:  Methods Mol Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  291-319     Citation Subset:  IM    
Affiliation:
Trius Therapeutics, San Diego, CA, USA, jfinn@triusrx.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Structure-based drug design on membrane protein targets: human integral membrane protein 5-lipoxygen...
Next Document:  Leveraging SBDD in Protein Therapeutic Development: Antibody Engineering.